Importantly, EphA2 is gaining increasing attention as target for cancer therapy because it is (i) upregulated on most solid tumors and on tumor endothelium, (ii) better accessible on tumors that often lack cell-associated ligands, (iii) functionally associated with tumor progression, and (iv) was recently reported to be a cancer stem cell marker [21], [22].Several EphA2-targeted therapeutic modalities have shown proof of concept in pre-clinical studies, including kinase inhibitors, antibodies, immunotoxins, engineered T cells, soluble receptors, and vaccines [22]–[24]. The gene discussed is EPHA2; the disease is cancer.